Evidence map›Paper›PMID 39528439›Full record

ReviewCell death discovery2024

Advances in smart nanotechnology-supported photodynamic therapy for cancer.

Guangyao Li, Cong Wang, Binghui Jin, Tao Sun, Kang Sun, Shuang Wang, Zhe Fan

Abstract readReview
In one paragraph

Review in Cell death discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Navigating theNanoscale advances · 2026
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guangyao Li *Department of Oncology, Cancer Hospital of Dalian University of Technology, Dalian, China.
Cong Wang *Department of General Surgery, the Third People's Hospital of Dalian, Dalian Medical University, Dalian, China.
Binghui Jin *Department of General Surgery, the Third People's Hospital of Dalian, Dalian Medical University, Dalian, China.
Tao SunDepartment of Oncology, Cancer Hospital of Dalian University of Technology, Dalian, China.
Kang SunDepartment of Digestive Endoscopy, The First Affiliated Hospital of Dalian Medical University, Dalian, China. 15142447309@163.com.ORCID http://orcid.org/0009-0007-5349-2845
Shuang WangDepartment of Endocrinology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China. wangshuang1986721@163.com.ORCID http://orcid.org/0009-0004-0264-6507
Zhe FanDepartment of General Surgery, the Third People's Hospital of Dalian, Dalian Medical University, Dalian, China. fanzhe1982@hotmail.com.ORCID http://orcid.org/0000-0002-2446-1122

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer has emerged as a formidable challenge in the 21st century, impacting society, public health, and the economy. Conventional cancer treatments often exhibit limited efficacy and considerable side effects, particularly in managing the advanced stages of the disease. Photodynamic therapy (PDT), a contemporary non-invasive therapeutic approach, employs photosensitizers (PS) in conjunction with precise light wavelengths to selectively target diseased tissues, inducing the generation of reactive oxygen species and ultimately leading to cancer cell apoptosis. In contrast to conventional therapies, PDT presents a lower incidence of side effects and greater precision in targeting. The integration of intelligent nanotechnology into PDT has markedly improved its effectiveness, as evidenced by the remarkable synergistic antitumor effects observed with the utilization of multifunctional nanoplatforms in conjunction with PDT. This paper provides a concise overview of the principles underlying PS and PDT, while also delving into the utilization of nanomaterial-based PDT in the context of cancer treatment.

Identifiers

PMID39528439
PMCPMC11554787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.